Indivior Pharmaceuticals (INDV) Cash & Equivalents (2021 - 2026)

Indivior Pharmaceuticals' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $175.0 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 52.96% year-over-year to $175.0 million in Q1 2026; TTM through Mar 2026 was $175.0 million, a 52.96% decrease from a year earlier, with the FY2025 full-year figure at $195.0 million, down 38.87% from the prior year.
• Cash & Equivalents slipped to $175.0 million in Q1 2026 per INDV's latest filing, from $195.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $774.0 million in Q4 2022 and bottomed at $175.0 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $345.5 million (2024), against an average of $388.2 million.
• Across the five-year window, Cash & Equivalents slumped 59.17% in 2023 and gained 0.95% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $774.0 million in 2022, then slumped by 59.17% to $316.0 million in 2023, then gained by 0.95% to $319.0 million in 2024, then plunged by 38.87% to $195.0 million in 2025, then dropped by 10.26% to $175.0 million in 2026.
• Per Business Quant, the three latest INDV Cash & Equivalents figures stand at $175.0 million (Q1 2026), $195.0 million (Q4 2025), and $445.0 million (Q3 2025).